目的：分析急性心肌梗死患者急诊PCI术后早期应用新活素的临床效果。方法：抽取2019年1月-2021年1月期间在我院急诊行PCI治疗的急性心肌梗死患者84例作为研究对象，以数字随机法对其进行分组，接受常规治疗的为对照组（n=42），在常规治疗的基础上早期应用新活素治疗的为研究组（n=42），随访时间为6个月，对比两组患者B型钠尿肽（NT-proBNP）水平、心功能指标（包括LVST、LVEF、LVD和CI）、心血管不良事件发生率及患者和家属对治疗效果的满意度。结果：（1）治疗前两组患者NT-proBNP水平对比无明显差异，（P＞0.05），治疗后研究组患者BNP水平明显低于对照组，（P＜0.05）。（2）治疗前两组患者各项心功能指标对比均无明显差异，治疗后研究组患者LVST、LVD检测量结果均明显低于对照组，LVEF、CI检测结果明显高于对照组，（P＜0.05）。（3）随访6个月，研究组患者心血管不良事件发生率明显比对照组患者低，（P＜0.05）。（4）研究组患者及家属对治疗效果的满意度明显比对照组患者及家属高，（P＜0.05）。结论：对于行PCI治疗的急性心肌梗死患者而言，术后早期应用新活素可显著改善患者心功能、降低患者再发心血管不良事件的风险，值得推广。 Objective: To analyze the clinical effect of early application of neovorin in patients with acute myocardial infarction after emergency PCI.Methods: Eighty-four patients with acute myocardial infarction (AMI) who underwent PCI in our hospital from January 2019 to January 2021 were randomly divided into control group (n=42) and routine treatment group (n=42). The patients who were treated with neovirin at early stage were followed up for 6 months.Results:(1) There was no significant difference in the level of NT-proBNP between the two groups before treatment (P >0.05). After treatment, the level of BNP in the study group was significantly lower than that in the control group (P <0.05).(2) There was no significant difference in cardiac function between the two groups before treatment. After treatment, LVST and LVD were significantly lower in the study group than in the control group, and LVEF and CI were significantly higher in the study group than in the control group (P <0.05).(3) The incidence of adverse cardiovascular events in the study group was significantly lower than that in the control group (P <0.05).(4) The satisfaction of the patients and their families in the study group was significantly higher than that in the control group (P <0.05).Conclusion: For the patients with acute myocardial infarction treated with PCI, early application of neovirubin can significantly improve the cardiac function and reduce the risk of recurrent adverse cardiac events.